---
title: "Prime Medicine, Inc. (PRME.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRME.US.md"
symbol: "PRME.US"
name: "Prime Medicine, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T17:38:36.296Z"
locales:
  - [en](https://longbridge.com/en/quote/PRME.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRME.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRME.US.md)
---

# Prime Medicine, Inc. (PRME.US)

## Company Overview

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [rimemedicine.com](https://rimemedicine.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 231 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.89% |  |
| Net Profit YoY | 1.80% |  |
| P/B Ratio | 6.66 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 510962666.57 |  |
| Revenue | 4034000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -216.07% | E |
| Profit Margin | -4917.55% | E |
| Gross Margin | -3884.23% | E |
| Revenue YoY | 4.89% | C |
| Net Profit YoY | 1.80% | C |
| Total Assets YoY | -10.19% | E |
| Net Assets YoY | -28.27% | E |
| Cash Flow Margin | 78.85% | C |
| OCF YoY | 4.89% | C |
| Turnover | 0.01 | E |
| Gearing Ratio | 73.98% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Prime Medicine, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.89%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "1.80%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.66",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "510962666.57",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4034000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-216.07%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4917.55%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-3884.23%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "4.89%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "1.80%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.19%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-28.27%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "78.85%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "4.89%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "73.98%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.58 | 277/385 | - | - | - |
| PB | 6.66 | 357/385 | 7.70 | 5.12 | 3.85 |
| PS (TTM) | 126.66 | 263/385 | 146.93 | 124.70 | 98.76 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 57% |
| Overweight | 1 | 7% |
| Hold | 4 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.92 |
| Highest Target | 11.00 |
| Lowest Target | 4.25 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PRME.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PRME.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PRME.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PRME.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**